Apixaban versus clopidoGRel on a background of aspirin in patient undergoing
Angioplasty for critical limb ischemia – AGRIPPA trial
Rodrigo B. Biagioni, Roberto Sacilotto, Luisa C. Biagioni, Marcone Sobreira, Edwaldo E. Joviliano, Ivan Casella, Ana T. Guillaumon, Giuliano G. Volpiani, Ronaldo Dávila, Ronald L. G. Flumignan, João C. Guerra, Ariane V. S. de Macedo, Renato D. Lopes, Eduardo Ramacciotti on behalf of the AGRIPPA PAD trial Investigators
CONCLUSION
In patients with critical limb ischemia undergoing infrapopliteal arterial endovascular intervention, apixaban 2 5 mg twice daily plus aspirin 100 mg for 12 months reduced the composite of reintervention, major amputation, restenosis/occlusion or MACE without increasing bleeding, when compared with clopidogrel 75 mg + aspirin 100 mg for 3 months followed by aspirin alone up to 12 months
